119 related articles for article (PubMed ID: 37852818)
1. Clinical stage and grade migration of localized prostate cancer at diagnosis during the past decade.
Beatrici E; Filipas DK; Stone BV; Labban M; Qian Z; Lipsitz SR; Lughezzani G; Buffi NM; Cole AP; Trinh QD
Urol Oncol; 2023 Dec; 41(12):483.e11-483.e19. PubMed ID: 37852818
[TBL] [Abstract][Full Text] [Related]
2. Inverse stage migration patterns in North American patients undergoing local prostate cancer treatment: a contemporary population-based update in light of the 2012 USPSTF recommendations.
Leyh-Bannurah SR; Karakiewicz PI; Pompe RS; Preisser F; Zaffuto E; Dell'Oglio P; Briganti A; Nafez O; Fisch M; Steuber T; Graefen M; Budäus L
World J Urol; 2019 Mar; 37(3):469-479. PubMed ID: 29992380
[TBL] [Abstract][Full Text] [Related]
3. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening.
Assel M; Dahlin A; Ulmert D; Bergh A; Stattin P; Lilja H; Vickers AJ
Eur Urol; 2018 Jun; 73(6):961-967. PubMed ID: 29066048
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk feature.
Faisal FA; Sundi D; Pierorazio PM; Ball MW; Humphreys EB; Han M; Epstein JI; Partin AW; Carter HB; Bivalacqua TJ; Schaeffer EM; Ross AE
BJU Int; 2014 Dec; 114(6b):E120-E129. PubMed ID: 24731026
[TBL] [Abstract][Full Text] [Related]
5. Association between PSA density and pathologically significant prostate cancer: The impact of prostate volume.
Omri N; Kamil M; Alexander K; Alexander K; Edmond S; Ariel Z; David K; Gilad AE; Azik H
Prostate; 2020 Dec; 80(16):1444-1449. PubMed ID: 32970856
[TBL] [Abstract][Full Text] [Related]
6. Uncovering the Changing Treatment Landscape for Low-risk Prostate Cancer in the USA from 2010 to 2020: Insights from the National Cancer Data Base.
Beatrici E; Labban M; Stone BV; Filipas DK; Reis LO; Lughezzani G; Buffi NM; Kibel AS; Cole AP; Trinh QD
Eur Urol; 2023 Dec; 84(6):527-530. PubMed ID: 37758573
[TBL] [Abstract][Full Text] [Related]
7. Changes in Prostate-specific Antigen Screening after the 2018 United States Preventive Services Task Force Recommendations and Through the COVID-19 Pandemic.
Qian Z; Chen X; Cole AP; Abdollah F; Choueiri TK; Kibel AS; Lipsitz SR; Iyer HS; Trinh QD
Eur Urol Oncol; 2024 Feb; 7(1):151-154. PubMed ID: 37487814
[TBL] [Abstract][Full Text] [Related]
8. Body mass index and prostate cancer severity: do obese men harbor more aggressive disease on prostate biopsy?
Chamie K; Oberfoell S; Kwan L; Labo J; Wei JT; Litwin MS
Urology; 2013 May; 81(5):949-55. PubMed ID: 23477756
[TBL] [Abstract][Full Text] [Related]
9. Ethnic differences in prostate cancer presentation: a time for testing advocacy.
Batura D; Patel A; Gandhi A; Pradhan A; Bachoo S; Tetea AA; Bassett P; Hellawell G
World J Urol; 2023 Dec; 41(12):3543-3549. PubMed ID: 37821779
[TBL] [Abstract][Full Text] [Related]
10. Association of the USPSTF Grade D Recommendation Against Prostate-Specific Antigen Screening With Prostate Cancer-Specific Mortality.
Burgess L; Aldrighetti CM; Ghosh A; Niemierko A; Chino F; Huynh MJ; Efstathiou JA; Kamran SC
JAMA Netw Open; 2022 May; 5(5):e2211869. PubMed ID: 35576008
[TBL] [Abstract][Full Text] [Related]
11. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
12. Contemporary national trends in prostate cancer risk profile at diagnosis.
Fletcher SA; von Landenberg N; Cole AP; Gild P; Choueiri TK; Lipsitz SR; Trinh QD; Kibel AS
Prostate Cancer Prostatic Dis; 2020 Mar; 23(1):81-87. PubMed ID: 31235801
[TBL] [Abstract][Full Text] [Related]
13. Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men.
Preston MA; Gerke T; Carlsson SV; Signorello L; Sjoberg DD; Markt SC; Kibel AS; Trinh QD; Steinwandel M; Blot W; Vickers AJ; Lilja H; Mucci LA; Wilson KM
Eur Urol; 2019 Mar; 75(3):399-407. PubMed ID: 30237027
[TBL] [Abstract][Full Text] [Related]
14. Changes in the outcome of prostate biopsies after preventive task force recommendation against prostate-specific antigen screening.
Zakaria AS; Dragomir A; Brimo F; Kassouf W; Tanguay S; Aprikian A
BMC Urol; 2018 Aug; 18(1):69. PubMed ID: 30126402
[TBL] [Abstract][Full Text] [Related]
15. Stage and Grade Migration in Prostate Cancer Treated With Radical Prostatectomy in a Large German Multicenter Cohort.
Boehm K; Borgmann H; Ebert T; Höfner T; Khaljani E; Schmid M; Schulze-Seemann W; Weib P; Herden J
Clin Genitourin Cancer; 2021 Apr; 19(2):162-166.e1. PubMed ID: 33526328
[TBL] [Abstract][Full Text] [Related]
16. Changes observed in prostate biopsy practices in an inner city hospital with a high risk patient population following the 2012 uspstf psa screening recommendations.
Tam AW; Khusid J; Inoyatov I; Becerra AZ; Davila J; Chouhan JD; Weiss JP; Hyacinthe LM; McNeil BK; Winer AG
Int Braz J Urol; 2018; 44(4):697-703. PubMed ID: 29617073
[TBL] [Abstract][Full Text] [Related]
17. A proposal of a new nomogram for predicting upstaging in contemporary D'Amico low-risk prostate cancer patients.
Leyh-Bannurah SR; Dell'Oglio P; Tian Z; Schiffmann J; Shariat SF; Suardi N; Francesco M; Alberto B; Heinzer H; Huland H; Graefen M; Budäus L; Karakiewicz PI
World J Urol; 2017 Feb; 35(2):189-197. PubMed ID: 27289238
[TBL] [Abstract][Full Text] [Related]
18. Abrogation of survival disparity between Black and White individuals after the USPSTF's 2012 prostate-specific antigen-based prostate cancer screening recommendation.
Kim IE; Jang TL; Kim S; Modi PK; Singer EA; Elsamra SE; Kim IY
Cancer; 2020 Dec; 126(23):5114-5123. PubMed ID: 32888321
[TBL] [Abstract][Full Text] [Related]
19. Association between Basal Total Testosterone Levels and Prostate Cancer D'Amico Risk Classes.
Tafuri A; Sebben M; Pirozzi M; Processali T; Shakir A; Rizzetto R; Amigoni N; Brunelli M; Baccaglini W; Migliorini F; Siracusano S; Artibani W; Porcaro AB
Urol Int; 2020; 104(9-10):716-723. PubMed ID: 32460298
[TBL] [Abstract][Full Text] [Related]
20. ESTRO-ACROP recommendations for evidence-based use of androgen deprivation therapy in combination with external-beam radiotherapy in prostate cancer.
Schmidt-Hegemann NS; Zamboglou C; Mason M; Mottet N; Hinnen K; De Meerleer G; Cozzarini C; Maingon P; Henry A; Spahn M; Cornford P; Belka C; Wiegel T
Radiother Oncol; 2023 Jun; 183():109544. PubMed ID: 36813168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
